Rifampicin (Rif)-resistant tuberculosis (TB) on GeneXpert in Mumbai, India: How effective is the best derived empiric regimen? Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India Source: Eur Respir J , 49 (3) 1601699; DOI: 10.1183/13993003.01699-2016 Year: 2017
Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures? Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
A comparison of drug sensitivity pattern in category-I failure versus category-I relapse pulmonary TB patients attending a tertiary care hospital in South Punjab, Pakistan. Is WHO category-II ATT regimen appropriate? Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Treatment outcome of multi-drug resistant tuberculosis in Varanasi, India Source: Eur Respir J 2002; 20: Suppl. 38, 615s Year: 2002
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Study on drug sensitivity patterns in tuberculosis in tertiary care in Mumbai Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017 Year: 2017
Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
In vitro susceptibility of TB- and MDR-TB-strains against linezolid at a local center in Berlin/GermanySource: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013
Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Resistance of Mycobacterium tuberculosis to the first-line (MDR) and second line (XDR) anti tuberculosis drugs in the south western zone of Nigeria: A- 3 year retrospective study Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Study of prevalence of drug resistance in tuberculosis (TB) patients attending a tertiary care hospital at Mumbai Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016